Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

3E Extension Study (3E Ex)

This study is ongoing, but not recruiting participants.
Major Science and Technology Special Project of China 12th Five-year
Information provided by (Responsible Party):
Nanfang Hospital of Southern Medical University Identifier:
First received: April 14, 2013
Last updated: June 17, 2014
Last verified: June 2014
The purpose of this study is to evaluate the long-term efficacy and safety of entecavir 0.5 mg/d + adefovir 10 mg/d for treatment experienced chronic hepatitis B patients.

Condition Intervention Phase
Chronic Hepatitis B
Drug: oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study

Resource links provided by NLM:

Further study details as provided by Nanfang Hospital of Southern Medical University:

Primary Outcome Measures:
  • Percentages of patients achieving HBV DNA< 300copies/mL at week 144 [ Time Frame: Week 144 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percentages of patients achieving HBV DNA <300copies/mL at week 48/96 [ Time Frame: Week 48 & 96 ] [ Designated as safety issue: No ]
  • The log10 reduction in HBV DNA from baseline of DRAGON study at week 48/96/144 [ Time Frame: Week 48 & 96 &144 ] [ Designated as safety issue: No ]
  • Percentage of patients with HBeAg loss or HBeAg seroconversion at week 48/96/144. [ Time Frame: Week 48 & 96 & 144 ] [ Designated as safety issue: No ]
  • Percentage of patients with ALT normalization at week 48/96/144 [ Time Frame: Week 48 & 96 & 144 ] [ Designated as safety issue: No ]

Estimated Enrollment: 600
Study Start Date: March 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Treatment group Drug: oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who completed the EXPLORE or EXCEL studies, or subjects with hepatitis flare after treatment withdrawal in EFFORT study.
  • Subjects who are willing to participate the extension study.

Exclusion Criteria:

  • Subjects who could not compliance with the protocol judged by investigators
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01834508

  Hide Study Locations
China, Beijing
302 Military Hospital Of China
Beijing, Beijing, China
Beijing Ditan Hospita
Beijing, Beijing, China
Beijing Friendship Hospital Attached To The Capital Medical University
Beijing, Beijing, China
BeiJing YouAn Hospital ,Capital Medical University
Beijing, Beijing, China
Department of infectious disease, First Hospital of Peking University
Beijing, Beijing, China
People's Hospital Under Beijnig University
Beijing, Beijing, China
China, Chongqing
The Second Affiliated of ChongQing University of Medical Science
Chongqing, Chongqing, China
China, Fujian
The First Affiliated Hospital of Fujian Medical University
FuZhou, Fujian, China
China, Guangdong
The First People's Hospital of Foshan
FoShan, Guangdong, China
Department of Infectious Disease, Nanfang Hospital
Guangzhou, Guangdong, China
GuangDong Provincial People's hospital
GuangZhou, Guangdong, China
No. 8 People's Hospital In GuangZhou
Guangzhou, Guangdong, China
The Third Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
China, Guangxi
First Affiliated Hospital of Guangxi Medical University
NanNing, Guangxi, China
China, Hubei
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
China, Hunan
Xiangya Hospital Central-South Univrsity
Changsha, Hunan, China
China, Jiangsu
No.81 Hospital of PLA
Nanjing, Jiangsu, China
China, Jilin
First Hospital .Jilin Unniversity
Changchun, Jilin, China
China, Liaoning
ShengJing Hospital of China Medical University
Shengyang, Liaoning, China
China, Shandong
JiNan Infectious Diseases Hospital
Jinan, Shandong, China
China, Shanghai
Changhai Hospital affiliated to Second Military Medical University
Shanghai, Shanghai, China
Huashan Hospital,Fudan University
Shanghai, Shanghai, China
No.85 Hospital of PLA
Shanghai, Shanghai, China
Shanghai Ruijin Hospital
Shanghai, Shanghai, China
China, Shanxi
Tangdu Hospital
XiAn, Shanxi, China
China, Sichuan
West China Hospital.SiChuan University
Chengdu, Sichuan, China
China, Zhejiang
HangZhou No.6 People Hospital
Hangzhou, Zhejiang, China
The First Affiliated Hospital of College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Sponsors and Collaborators
Nanfang Hospital of Southern Medical University
Major Science and Technology Special Project of China 12th Five-year
  More Information

Responsible Party: Nanfang Hospital of Southern Medical University Identifier: NCT01834508     History of Changes
Other Study ID Numbers: MOH-07 
Study First Received: April 14, 2013
Last Updated: June 17, 2014
Health Authority: China: Food and Drug Administration

Keywords provided by Nanfang Hospital of Southern Medical University:
Experienced Treatment

Additional relevant MeSH terms:
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Adefovir dipivoxil
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents processed this record on January 17, 2017